According to the participant's experience, the tumours most often requiring primary prophylaxis with G-CSF are: sarcomas (77.1%; n: 54), breast cancer (72.9%; n: 51), germ cell tumours (62.9%; n: 44) and bone tumours (58.6%; n: 41). This evidence concerns the gene CSF3 and breast cancer.